Spectrum Pharmaceuticals is a commercial-stage biotechnology company with fully integrated commercial and drug development operation. The Company and its subsidiaries have six marketed oncology/hematology products, three for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia and one for multiple myeloma. There are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.